Enliven Therapeutics (ELVN) Insider Trading & Ownership $21.72 -0.18 (-0.82%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Enliven Therapeutics (NASDAQ:ELVN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)8Amount OfInsider Selling(Last 12 Months)$36.80 M Get ELVN Insider Trade Alerts Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ELVN Insider Buying and Selling by Quarter Enliven Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/7/2025Anish PatelCOOSell6,667$21.93$146,207.31 2/5/2025Benjamin HohlCFOSell1,000$22.52$22,520.00 1/27/2025Benjamin HohlCFOSell3,250$21.59$70,167.50 1/7/2025Anish PatelCOOSell21,700$24.18$524,706.00 1/3/2025Benjamin HohlCFOSell1,000$25.04$25,040.00 12/30/2024Benjamin HohlCFOSell900$22.51$20,259.00 12/27/2024Benjamin HohlCFOSell3,350$22.15$74,202.50 11/27/2024Benjamin HohlCFOSell5,250$24.89$130,672.50 10/28/2024Benjamin HohlCFOSell6,250$28.56$178,500.00 10/18/2024Anish PatelCOOSell716$30.00$21,480.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/18/2024Benjamin HohlCFOSell814$30.00$24,420.00 10/18/2024Joseph P LyssikatosInsiderSell847$30.00$25,410.00 10/18/2024Richard A HeymanDirectorSell817$30.00$24,510.00 10/18/2024Samuel KintzCEOSell924$30.00$27,720.00 10/15/2024Richard A HeymanDirectorSell1,270$27.67$35,140.90 10/9/2024Joseph P LyssikatosInsiderSell37,878$28.16$1,066,644.48 10/9/2024Samuel KintzCEOSell16,710$28.15$470,386.50 10/8/2024Rahul D BallalDirectorSell10,420$28.17$293,531.40 10/7/2024Benjamin HohlCFOSell1,270$27.51$34,937.70 10/7/2024Joseph P LyssikatosInsiderSell2,707$27.61$74,740.27 10/7/2024Samuel KintzCEOSell2,730$27.50$75,075.00 10/4/2024Benjamin HohlCFOSell10,218$27.51$281,097.18 10/4/2024Joseph P LyssikatosInsiderSell7,522$27.51$206,930.22 10/4/2024Richard A HeymanDirectorSell2,825$27.51$77,715.75 10/4/2024Samuel KintzCEOSell12,206$27.51$335,787.06 10/1/2024Joseph P LyssikatosInsiderSell527$27.54$14,513.58 10/1/2024Richard A HeymanDirectorSell518$27.54$14,265.72 10/1/2024Samuel KintzCEOSell526$27.54$14,486.04 9/30/2024Benjamin HohlCFOSell2,000$25.33$50,660.00 9/27/2024Benjamin HohlCFOSell4,250$24.27$103,147.50 8/29/2024Joseph P LyssikatosInsiderSell12,000$22.49$269,880.00 8/27/2024Benjamin HohlCFOSell4,250$22.54$95,795.00 8/26/2024Samuel KintzCEOSell12,000$22.89$274,680.00 8/15/2024Richard A HeymanDirectorSell1,270$23.25$29,527.50 7/31/2024Benjamin HohlCFOSell991$27.53$27,282.23 7/31/2024Joseph P LyssikatosInsiderSell3,099$27.56$85,408.44 7/31/2024Richard A HeymanDirectorSell1,702$27.51$46,822.02 7/31/2024Samuel KintzCEOSell2,270$27.56$62,561.20 7/29/2024Benjamin HohlCFOSell5,250$26.68$140,070.00 7/29/2024Joseph P LyssikatosInsiderSell12,000$26.70$320,400.00 Critical ‘Buy Now’ Alert on My Favorite Stock! (Ad)My absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>>7/25/2024Samuel KintzCEOSell12,000$24.92$299,040.00 7/15/2024Anish PatelCOOSell30,978$25.05$775,998.90 7/15/2024Richard A HeymanDirectorSell1,270$24.80$31,496.00 7/12/2024Anish PatelCOOSell17,475$25.07$438,098.25 7/12/2024Benjamin HohlCFOSell3,000$25.07$75,210.00 6/27/2024Benjamin HohlCFOSell4,250$22.57$95,922.50 6/25/2024Samuel KintzCEOSell12,000$21.66$259,920.00 6/6/2024Anish PatelCOOSell1,133$20.06$22,727.98 5/28/2024Benjamin HohlCFOSell4,250$23.18$98,515.00 5/28/2024Samuel KintzCEOSell12,000$23.18$278,160.00 5/16/2024Rishi GuptaDirectorSell1,033,300$22.14$22,877,262.00 5/14/2024Anish PatelCOOSell1,107$25.00$27,675.00 5/9/2024Anish PatelCOOSell260$25.06$6,515.60 5/6/2024Anish PatelCOOSell4,875$22.72$110,760.00 5/3/2024Benjamin HohlCFOSell1,000$22.50$22,500.00 4/29/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 4/29/2024Joseph P. LyssikatosinsiderSell12,000$17.92$215,040.00 4/25/2024Samuel KintzCEOSell12,000$16.89$202,680.00 4/15/2024Richard A HeymanDirectorSell1,270$19.99$25,387.30 4/11/2024Anish PatelCOOSell17,500$25.03$438,025.00 4/11/2024Benjamin HohlCFOSell14,000$24.72$346,080.00 4/11/2024Joseph P. LyssikatosinsiderSell30,000$25.04$751,200.00 4/11/2024Rahul D BallalDirectorSell53,400$23.95$1,278,930.00 4/11/2024Samuel KintzCEOSell47,709$25.04$1,194,633.36 4/8/2024Anish PatelCOOSell4,875$18.60$90,675.00 4/4/2024Rahul D BallalDirectorSell3,485$19.15$66,737.75 4/1/2024Joseph P. LyssikatosinsiderSell12,000$18.60$223,200.00 4/1/2024Rahul D BallalDirectorSell3,237$19.08$61,761.96 3/27/2024Benjamin HohlCFOSell3,250$18.25$59,312.50 3/25/2024Samuel KintzCEOSell12,000$17.56$210,720.00 3/19/2024Richard A HeymanDirectorSell1,270$14.50$18,415.00 3/6/2024Anish PatelCOOSell4,875$15.64$76,245.00 2/29/2024Joseph P. LyssikatosinsiderSell12,000$16.42$197,040.00 2/27/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 (Data available from 1/1/2013 forward) ELVN Insider Trading Activity - Frequently Asked Questions Who is on Enliven Therapeutics's Insider Roster? The list of insiders at Enliven Therapeutics includes 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta, and Samuel Kintz. Learn more on insiders at ELVN. What percentage of Enliven Therapeutics stock is owned by insiders? 29.20% of Enliven Therapeutics stock is owned by insiders. Learn more on ELVN's insider holdings. Which Enliven Therapeutics insiders have been selling company stock? The following insiders have sold ELVN shares in the last 24 months: 5Am Partners Vi, Llc ($17,502,500.00), Anish Patel ($3,007,839.55), Benjamin Hohl ($2,295,859.54), Joseph P Lyssikatos ($2,063,926.99), Rahul D Ballal ($1,700,961.11), Richard A Heyman ($349,650.29), Rishi Gupta ($22,877,262.00), and Samuel Kintz ($4,548,397.78). How much insider selling is happening at Enliven Therapeutics? Insiders have sold a total of 2,880,809 Enliven Therapeutics shares in the last 24 months for a total of $56,201,158.94 sold. Enliven Therapeutics Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Compensation: $866.41kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder & Chief Scientific Officer Compensation: $632.67kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Compensation: $686.19kMr. Anish Patel Pharm.D. (Age 43)Co-Founder & COO Mr. Benjamin Hohl (Age 34)CFO & Head of Corporate Development Compensation: $488.5k13 recent tradesDr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development More Insider Trading Tools from MarketBeat Related Companies Biohaven Insider Buying Recursion Pharmaceuticals Insider Buying PTC Therapeutics Insider Buying Organon & Co. Insider Buying Ultragenyx Pharmaceutical Insider Buying Avidity Biosciences Insider Buying ADMA Biologics Insider Buying Arcellx Insider Buying Akero Therapeutics Insider Buying Rhythm Pharmaceuticals Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:ELVN) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersThe $3 Trillion AI GlitchForget the Border Crisis, China, and the Deep State. The biggest threat to Trump’s 2nd term could begin wit...Banyan Hill Publishing | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredAmerica cannot power AIPresident Donald Trump has put one final nail in Joe Biden’s coffin… He just revoked a 2023 executive order...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELVN Stock Alerts